Kathmere Capital Management LLC Sells 967 Shares of Zoetis Inc. (NYSE:ZTS)

Kathmere Capital Management LLC reduced its stake in Zoetis Inc. (NYSE:ZTS) by 15.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,201 shares of the company’s stock after selling 967 shares during the period. Kathmere Capital Management LLC’s holdings in Zoetis were worth $856,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Ballentine Partners LLC increased its stake in shares of Zoetis by 1.1% during the first quarter. Ballentine Partners LLC now owns 12,283 shares of the company’s stock valued at $2,022,000 after purchasing an additional 132 shares in the last quarter. Harmony Asset Management LLC bought a new position in shares of Zoetis during the first quarter valued at approximately $1,656,000. Callahan Advisors LLC increased its stake in shares of Zoetis by 9.8% during the first quarter. Callahan Advisors LLC now owns 14,388 shares of the company’s stock valued at $2,369,000 after purchasing an additional 1,283 shares in the last quarter. Diversify Wealth Management LLC increased its stake in shares of Zoetis by 18.2% during the first quarter. Diversify Wealth Management LLC now owns 29,821 shares of the company’s stock valued at $4,635,000 after purchasing an additional 4,597 shares in the last quarter. Finally, Xponance Inc. increased its stake in shares of Zoetis by 0.6% during the first quarter. Xponance Inc. now owns 107,531 shares of the company’s stock valued at $17,705,000 after purchasing an additional 592 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 2.4%

NYSE:ZTS opened at $154.91 on Friday. The company’s 50 day moving average price is $161.32 and its 200-day moving average price is $161.84. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The company has a quick ratio of 1.04, a current ratio of 1.74 and a debt-to-equity ratio of 1.12. The stock has a market cap of $68.97 billion, a price-to-earnings ratio of 27.81, a PEG ratio of 2.57 and a beta of 0.91.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. During the same quarter in the previous year, the firm posted $1.38 EPS. The firm’s revenue was up 1.4% on a year-over-year basis. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.29%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis’s dividend payout ratio (DPR) is presently 35.91%.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president owned 15,129 shares of the company’s stock, valued at approximately $2,571,930. The trade was a 4.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.18% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. UBS Group decreased their target price on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, May 7th. Stifel Nicolaus downgraded shares of Zoetis from a “buy” rating to a “hold” rating and decreased their target price for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Piper Sandler increased their price target on shares of Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a report on Monday, May 12th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $212.13.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.